China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), branded as Menhycia, in Indonesia, with the first subject already enrolled. This pivotal study aims to evaluate both the safety and immunogenicity of the vaccine in individuals aged 18 to 55.
Menhycia received marketing approval in China in June 2022, marking a significant milestone as the first of its kind developed in Asia.- Flcube.com
